Insignis Therapeutics

[{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IN-001","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Insignis Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"5","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insignis Receives FDA Fast Track Designation For IN-001 in Anaphylaxis Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Insignis Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Insignis Therapeutics \/ Not Applicable"}]